Skip to main content

Sethera Therapeutics Appoints Biotech Pioneer Dr. Robert Langer to Head and Chair the Scientific Advisory Board and Brigadier General Larry Lunt to Board of Directors

By: Newsfile

Salt Lake City, Utah--(Newsfile Corp. - February 5, 2025) - Sethera Therapeutics announced the appointment of Dr. Robert Langer, a world-renowned scientist, entrepreneur, and co-founder of Moderna, to Head and Chair its Scientific Advisory Board. The company also welcomed Brigadier General Larry V. Lunt, USAF (Ret.), a distinguished leader with decades of strategic expertise, to its Board of Directors.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Scientific Leadership: Dr. Langer's expertise in drug delivery systems and tissue engineering will be invaluable in guiding Sethera's scientific strategy and advancing its pipeline of innovative peptide-based therapeutics.
  • Strategic Leadership: Brig. Gen. Lunt's strategic vision and proven ability to lead organizations through complex challenges will be essential as Sethera continues to grow and evolve.
  • Company's Position Strengthened: The addition of Dr. Langer and Brig. Gen. Lunt to Sethera's leadership team strengthens the company's position in the field of peptide therapeutics. With a focus on accessing complex molecular architectures, Sethera is developing therapies for a wide range of diseases and is poised to make significant contributions to the advancement of human health.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/239712_figure1.png

Click image above to view full announcement.


About Sethera Therapeutics

Sethera Therapeutics is a privately held biopharmaceutical company dedicated to transforming the field of peptide therapeutics. The company's proprietary platform technology enables the development of enzymatically-altered peptide-based therapies with enhanced efficacy, safety, and delivery. The Sethera platform potentially targets a wide range of therapeutic areas. Sethera is building a world-class team and is committed to advancing the field of peptide therapeutics and improving the lives of patients worldwide.

Contacts:

Chelli Miller
219-921-6823
chelli@contentcarnivores.com

Source: Sethera Therapeutics

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239712

Recent Quotes

View More
Symbol Price Change (%)
AMZN  215.75
+7.02 (3.36%)
AAPL  265.03
+1.28 (0.49%)
AMD  199.46
+8.51 (4.45%)
BAC  50.08
+0.11 (0.21%)
GOOG  304.15
+0.59 (0.19%)
META  670.90
+15.82 (2.41%)
MSFT  406.23
+2.30 (0.57%)
NVDA  182.88
+2.83 (1.57%)
ORCL  152.87
+3.86 (2.59%)
TSLA  406.79
+14.36 (3.66%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.